{"version":"1.0","provider_name":"Vistamedica","provider_url":"https:\/\/www.vistamedica.com\/main","author_name":"Diego A. Romero","author_url":"https:\/\/www.vistamedica.com\/main\/author\/daromixnet\/","title":"Nueva droga para el c\u00e1ncer de mama - Vistamedica","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"MWlsoTTzQ8\"><a href=\"https:\/\/www.vistamedica.com\/main\/2005\/03\/11\/nueva-droga-para-el-cancer-de-mama\/\">Nueva droga para el c\u00e1ncer de mama<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.vistamedica.com\/main\/2005\/03\/11\/nueva-droga-para-el-cancer-de-mama\/embed\/#?secret=MWlsoTTzQ8\" width=\"600\" height=\"338\" title=\"\u00abNueva droga para el c\u00e1ncer de mama\u00bb \u2014 Vistamedica\" data-secret=\"MWlsoTTzQ8\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.vistamedica.com\/main\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Se lanza en Espa\u00f1a Faslodex (fulvestrant), el primer y \u00fanico antagonista del receptor estrog\u00e9nico sin efecto agonista para el tratamiento del c\u00e1ncer de mama avanzado.Ya est\u00e1 disponible en Espa\u00f1a Faslodex (fulvestrant), un nuevo f\u00e1rmaco cuyo modo de acci\u00f3n \u00fanico supone un nuevo tipo de tratamiento hormonal del c\u00e1ncer de mama en las mujeres con receptores estrog\u00e9nicos positivos. Se trata del primer y \u00fanico antagonista del receptor estrog\u00e9nico sin efecto agonista para el tratamiento del c\u00e1ncer de mama avanzado, que se administra mediante una inyecci\u00f3n intramuscular mensual."}